T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• T cells are crucial for anti-tumor immunity.
• Aberrant B7 family member expression aids tumor evasion.
• B7-H3 is a potential target for T cell-mediated cytotoxicity in hematologic malignancies.

Purpose of the Study:

• To analyze B7-H3 expression on hematologic tumor cells.
• To evaluate the efficacy of a bispecific antibody (anti-CD3 × anti-B7-H3, B7-H3Bi-Ab) in redirecting T cells against B7-H3 positive hematologic tumors.

Main Methods:

• Investigated B7-H3 expression on various hematologic tumor cell lines (Thp-1, K562, Daudi) and primary cultures.
• Assessed T cell cytotoxicity using lactate dehydrogenase assay, flow cytometry, ELISA, and luciferase assay.
• Measured cytokine secretion (IFN-γ, TNF-α, IL-2) and CD69 expression.

Main Results:

• B7-H3Bi-Ab-armed T cells demonstrated significantly enhanced cytotoxicity against hematologic tumor cells compared to unarmed T cells.
• Armed T cells secreted higher levels of IFN-γ, TNF-α, IL-2, and Granzyme B.
• Increased expression of the activating marker CD69 was observed on armed T cells.

Conclusions:

• B7-H3Bi-Ab effectively enhances T cell-mediated killing of hematologic tumor cells.
• B7-H3 represents a promising novel target for immunotherapy in hematologic malignancies.